Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7026289 | 0.81 | ALOX15 (0.41) | ALOX15BLMPMP22KMT2ACA1 | |
| SCHEMBL293079 | 0.81 | CA1 (0.39) | ALOX15BLMPMP22KMT2ACA1 | |
| SCHEMBL28842913 | 0.80 | CA1 (0.37) | ALOX15BLMPMP22KMT2ACA1 | |
| SCHEMBL11694381 | 0.80 | ALOX15 (0.44) | ALOX15BLMPMP22KMT2ACA1 | |
| SCHEMBL1230306 | 0.80 | CA1 (0.37) | ALOX15BLMPMP22KMT2ACA1 | |
| SCHEMBL28650038 | 0.79 | SLC1A3 (0.41) | ALOX15BLMPMP22KMT2ACA1 | |
| SCHEMBL28601320 | 0.78 | CA1 (0.37) | ALOX15BLMPMP22CA1CA2 | |
| SCHEMBL6369370 | 0.78 | ALOX15 (0.43) | ALOX15BLMPMP22KMT2ACA1 | |
| SCHEMBL21906568 | 0.78 | CA2 (0.61) | ALOX15BLMPMP22KMT2ACA1 | |
| SCHEMBL9814736 | 0.78 | FOLH1 (0.46) | ALOX15BLMPMP22KMT2ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | ALOX15 634/4885BLM 2953/4885PMP22 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.